<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35305605</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2377</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>19</Day></PubDate></JournalIssue><Title>BMC neurology</Title><ISOAbbreviation>BMC Neurol</ISOAbbreviation></Journal><ArticleTitle>Peak expiratory flow is a reliably household pulmonary function parameter correlates with disease severity and survival of patients with amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>105</StartPage><MedlinePgn>105</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">105</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12883-022-02635-z</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Amyotrophic lateral sclerosis (ALS) is an incurable and fatal neurodegenerative disease; most ALS patients die within 3 to 5&#xa0;years after symptom onset, usually as a consequence of respiratory failure. In the present study, we aim to screen the survival-related pulmonary function parameters, and to explore the predictive value of peak expiratory flow (PEF) in disease severity and prognosis in patients with ALS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The discovery cohort included 202 ALS patients, and the demographic and clinical characteristics of eligible patients were collected and pulmonary function tests were performed using MS-PFT spirometer. In the validation cohort, 62 newly diagnosed ALS patients performed the pulmonary function test by MS-PFT spirometer and household peak flow meter (KOKA) simultaneously.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 12 pulmonary function parameters, FVC, FEV1, PEF, MEF75%, and MVV were identified to be independent predictive factors for survival. PEF was highly correlated with FVC (r&#x2009;=&#x2009;0.797), MVV (r&#x2009;=&#x2009;0.877), FEV1 (r&#x2009;=&#x2009;0.847), and MEF75% (r&#x2009;=&#x2009;0.963). Besides, the values of PEF were positively associated with disease severity (ALSFRS-R score, r<sub>s</sub>&#x2009;=&#x2009;0.539, P&#x2009;&lt;&#x2009;0.0001), and negatively associated with progression rate (&#x394;ALSFRS-R, r<sub>s</sub>&#x2009;=&#x2009;-0.316, P&#x2009;&lt;&#x2009;0.0001). Finally, we also confirmed that the values of KOKA-measured PEF were highly correlated with the ones measured using MS-PFT spirometer (r&#x2009;=&#x2009;0.9644, p&#x2009;&lt;&#x2009;0.0001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our work emphasizes the critical role of PFTs in predicting prognosis of ALS patients. PEF is an easily available pulmonary function index, which is also a promising indicator in predicting disease severity and survival for ALS patients.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Qi-Jie</ForeName><Initials>QJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Fujian Institute of Neurology, The First Affiliated Hospital, Fujian Medical University, 20 Chazhong Road, Fuzhou, 350005, China. qijiezhang86@fjmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Huang</LastName><ForeName>Jian-Chai</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chen</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, Fujian Institute of Neurology, The First Affiliated Hospital, Fujian Medical University, 20 Chazhong Road, Fuzhou, 350005, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Liu-Qing</ForeName><Initials>LQ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Fujian Institute of Neurology, The First Affiliated Hospital, Fujian Medical University, 20 Chazhong Road, Fuzhou, 350005, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Qi-Fu</ForeName><Initials>QF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Fujian Institute of Neurology, The First Affiliated Hospital, Fujian Medical University, 20 Chazhong Road, Fuzhou, 350005, China. fmugqf@fjmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2021J01209</GrantID><Agency>Natural Science Foundation of Fujian Province</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Neurol</MedlineTA><NlmUniqueID>100968555</NlmUniqueID><ISSNLinking>1471-2377</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012129" MajorTopicYN="N">Respiratory Function Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014797" MajorTopicYN="N">Vital Capacity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Peak expiratory flow</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword><Keyword MajorTopicYN="N">Survival</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>20</Day><Hour>20</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35305605</ArticleId><ArticleId IdType="pmc">PMC8933978</ArticleId><ArticleId IdType="doi">10.1186/s12883-022-02635-z</ArticleId><ArticleId IdType="pii">10.1186/s12883-022-02635-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, van den Berg LH. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedermeyer S, Murn M, Choi PJ. Respiratory failure in amyotrophic lateral sclerosis. Chest. 2019;155:401&#x2013;408. doi: 10.1016/j.chest.2018.06.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2018.06.035</ArticleId><ArticleId IdType="pubmed">29990478</ArticleId></ArticleIdList></Reference><Reference><Citation>Raaphorst J, Tuijp J, Verweij L, Westermann EJ, van der Kooi AJ, Gaytant MA, van den Berg LH, de Visser M, Kampelmacher MJ. Treatment of respiratory impairment in patients with motor neuron disease in the Netherlands: patient preference and timing of referral. Eur J Neurol. 2013;20:1524&#x2013;1530. doi: 10.1111/ene.12096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12096</ArticleId><ArticleId IdType="pubmed">23398243</ArticleId></ArticleIdList></Reference><Reference><Citation>Sancho J, Servera E, Ba&#xf1;uls P, Marin J. Predictors of need for noninvasive ventilation during respiratory tract infections in medically stable, non-ventilated subjects with amyotrophic lateral sclerosis. Respir Care. 2015;60:492&#x2013;497. doi: 10.4187/respcare.03553.</Citation><ArticleIdList><ArticleId IdType="doi">10.4187/respcare.03553</ArticleId><ArticleId IdType="pubmed">25406348</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumann F, Henderson RD, Morrison SC, Brown M, Hutchinson N, Douglas JA, Robinson PJ, McCombe PA. Use of respiratory function tests to predict survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:194&#x2013;202. doi: 10.3109/17482960902991773.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960902991773</ArticleId><ArticleId IdType="pubmed">19452343</ArticleId></ArticleIdList></Reference><Reference><Citation>JavadMousavi SA, Zamani B, ShahabiShahmiri S, Rohani M, Shahidi GA, Mostafapour E, Hemasian H, Raji H. Pulmonary function tests in patients with amyotrophic lateral sclerosis and the association between these tests and survival. Iran J Neurol. 2014;13:131&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4240929</ArticleId><ArticleId IdType="pubmed">25422731</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechtzin N, Cudkowicz ME, de Carvalho M, Genge A, Hardiman O, Mitsumoto H, Mora JS, Shefner J, Van den Berg LH, Andrews JA. Respiratory measures in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:321&#x2013;330. doi: 10.1080/21678421.2018.1452945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1452945</ArticleId><ArticleId IdType="pubmed">29566571</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain P, Kavuru MS, Emerman CL, Ahmad M. Utility of peak expiratory flow monitoring. Chest. 1998;114:861&#x2013;876. doi: 10.1378/chest.114.3.861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.114.3.861</ArticleId><ArticleId IdType="pubmed">9743179</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulmonary function group, respiratory branch, Chinese Medical Association Guidelines for pulmonary function test - peak expiratory flow and its variation rate. Chin J Tuberc Respir Dis. 2017;40:426&#x2013;430.</Citation></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revised: world federation of neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. ATS/ERS task force standardisation of spirometry. Eur Respir J. 2005;26:319&#x2013;338. doi: 10.1183/09031936.05.00034805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.05.00034805</ArticleId><ArticleId IdType="pubmed">16055882</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce R. Spirometry: an essential clinical measurement. Aust Fam Physician. 2005;34:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">15999163</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Zhang B, Chen R, Tang L, Liu R, Yang Y, Yang Y, Liu X, Ye S, Zhan S, Fan D. Natural history and clinical features of sporadic amyotrophic lateral sclerosis in China. J Neurol Neurosurg Psychiatry. 2015;86:1075&#x2013;1081. doi: 10.1136/jnnp-2015-310471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-310471</ArticleId><ArticleId IdType="pubmed">26124198</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, Zhang H, Shefner JM, Schoenfeld D, Cudkowicz ME. NEALS consortium. Functional outcome measures as clinical trial endpoints in ALS. Neurology. 2004;63:1933&#x2013;5. doi: 10.1212/01.WNL.0000144345.49510.4E.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000144345.49510.4E</ArticleId><ArticleId IdType="pubmed">15557515</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardiotis E, Siokas V, Sokratous M, Tsouris Z, Aloizou AM, Florou D, Dastamani M, Mentis AA, Brotis AG. Body mass index and survival from amyotrophic lateral sclerosis: a meta-analysis. Neurol Clin Pract. 2018;8:437&#x2013;444. doi: 10.1212/CPJ.0000000000000521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CPJ.0000000000000521</ArticleId><ArticleId IdType="pmc">PMC6276330</ArticleId><ArticleId IdType="pubmed">30564498</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu LQ, Hu W, Guo QF, Lai LL, Xu GR, Chen WJ, Wang N, Zhang QJ. Median nerve-neurophysiological index correlates with the survival of patients with amyotrophic lateral sclerosis. Front Neurol. 2020;11:570227. doi: 10.3389/fneur.2020.570227.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.570227</ArticleId><ArticleId IdType="pmc">PMC7642643</ArticleId><ArticleId IdType="pubmed">33193014</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirola A, De Mattia E, Lizio A, Sannicol&#xf2; G, Carraro E, Rao F, Sansone V, Lunetta C. The prognostic value of spirometric tests in amyotrophic lateral sclerosis patients. Clin Neurol Neurosurg. 2019;184:105456. doi: 10.1016/j.clineuro.2019.105456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2019.105456</ArticleId><ArticleId IdType="pubmed">31382080</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrasoma B, Balfe D, Naik T, Elsayegh A, Lewis M, Mosenifar Z. Pulmonary function in patients with amyotrophic lateral sclerosis at disease onset. Monaldi Arch Chest Dis. 2012;77:129&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">23461249</ArticleId></ArticleIdList></Reference><Reference><Citation>So JY, Lastra AC, Zhao H, Marchetti N, Criner GJ. Daily peak expiratory flow rate and disease instability in chronic obstructive pulmonary disease. Chronic Obstr Pulm Dis. 2015;3:398&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5559121</ArticleId><ArticleId IdType="pubmed">28848862</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez AA, Pessolano FA, Monteiro SG, Ferreyra G, Capria ME, Mesa L, Dubrovsky A, De Vito EL. Peak flow and peak cough flow in the evaluation of expiratory muscle weakness and bulbar impairment in patients with neuromuscular disease. Am J Phys Med Rehabil. 2002;81:506&#x2013;511. doi: 10.1097/00002060-200207000-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002060-200207000-00007</ArticleId><ArticleId IdType="pubmed">12131177</ArticleId></ArticleIdList></Reference><Reference><Citation>Thoracic Society of Australia and New Zealand Peak flow meter use in asthma management. Med J Aust. 1996;164:727&#x2013;730. doi: 10.5694/j.1326-5377.1996.tb122272.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.5694/j.1326-5377.1996.tb122272.x</ArticleId><ArticleId IdType="pubmed">8668080</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma V, Gupta RK, Jamwal DS, Raina SK, Langer B, Kumari R. Prevalence of chronic respiratory disorders in a rural area of North West India: a population-based study. J Family Med Prim Care. 2016;5:416&#x2013;449. doi: 10.4103/2249-4863.192342.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2249-4863.192342</ArticleId><ArticleId IdType="pmc">PMC5084572</ArticleId><ArticleId IdType="pubmed">27843852</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Fernandes SR, Pereira M, Gromicho M, Santos MO, Alves I, Pinto S, Swash M. Respiratory function tests in amyotrophic lateral sclerosis: the role of maximal voluntary ventilation. J Neurol Sci. 2022;434:120143. doi: 10.1016/j.jns.2022.120143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2022.120143</ArticleId><ArticleId IdType="pubmed">35030382</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada S, Hashizume A, Hijikata Y, Inagaki T, Suzuki K, Kondo N, Kawai K, Noda S, Nakanishi H, Banno H, Hirakawa A, Koike H, Halievski K, Jordan CL, Katsuno M, Sobue G. Decreased peak expiratory flow associated with muscle fiber-type switching in spinal and bulbar muscular atrophy. PLoS One. 2016;11:e0168846. doi: 10.1371/journal.pone.0168846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0168846</ArticleId><ArticleId IdType="pmc">PMC5179045</ArticleId><ArticleId IdType="pubmed">28005993</ArticleId></ArticleIdList></Reference><Reference><Citation>Paillisse C, Lacomblez L, Dib M, Bensimon G, Garcia-Acosta S, Meininger V. Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6:37&#x2013;44. doi: 10.1080/14660820510027035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820510027035</ArticleId><ArticleId IdType="pubmed">16036424</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, de Carvalho M. Correlation between Forced Vital Capacity and Slow Vital Capacity for the assessment of respiratory involvement in amyotrophic lateral sclerosis: a prospective study. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:86&#x2013;91. doi: 10.1080/21678421.2016.1249486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1249486</ArticleId><ArticleId IdType="pubmed">27915482</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, de Carvalho M. Comparison of slow and forced vital capacities on ability to predict survival in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:528&#x2013;533. doi: 10.1080/21678421.2017.1354995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1354995</ArticleId><ArticleId IdType="pubmed">28741375</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Meng L, Kulke SF, Rudnicki SA, Wolff AA, Bozik ME, Malik FI, Shefner JM. Association between decline in slow vital capacity and respiratory insufficiency, use of assisted ventilation, tracheostomy, or death in patients with amyotrophic lateral sclerosis. JAMA Neurol. 2018;75:58&#x2013;64. doi: 10.1001/jamaneurol.2017.3339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.3339</ArticleId><ArticleId IdType="pmc">PMC5833488</ArticleId><ArticleId IdType="pubmed">29181534</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>